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Background
Cannabis sativa is a herbaceous plant that shares the 
botanical group Cannabaceae with the hop plant. The 
stems of the plant can be retted – a process of steeping 
or watering – to form hemp, which has been widely used 
in rope making and other fabrics. The plant also contains 
a variety of cannabinoids, including delta-9-tetra-
hydrocannabinol (D9THC), which acts as the principal 
psychoactive component contributing to the activity of 
cannabis as a psychotropic drug. D9THC is understood 
to bind to cannabinoid receptors in the brain which 
normally bind the natural neurotransmitter anandamide 
(‘ananda’ meaning bliss in Sanskrit).
The cannabis plant grows easily and quickly in a range of 
climatic and soil conditions, including both tropical and 
temperate regions, and is increasingly cultivated indoors 
using hydroponic techniques which exploit the use of 
nutrient-rich liquids in place of soil. These properties 
mean that cannabis may be grown in almost every country 
worldwide so it is perhaps not surprising that cannabis 
has emerged as the world’s most commonly used illegal 
drug.1 The most recent survey by the European Drugs 
Monitoring Centre suggests, as a conservative estimate, 
that cannabis has been used at least once (lifetime 
prevalence) by more than 70 million European adults, with 
around 23 million using cannabis in the past year.2
The situation in the UK is little different. Although 
recreational use of cannabis was rare before the 1960s,3,4 
since then the UK has witnessed a dramatic increase in 
cannabis use. Recent information from the 2007/2008 
British Crime Survey,5 focusing on household samples of 
people aged 16–59 years living in England and Wales, 
suggests that cannabis was by far the most commonly 
used illegal drug, with 7.4% of this population reporting 
cannabis use in the preceding year. The use of cannabis 
is particularly prevalent in the young, with the highest 
levels of use generally being reported among the 15- to 
24-year-old age group;2 for example, in Scotland cannabis 
use has been reported in 13% of 15-year-old boys and 
10% of 15-year-old girls.6 
Partly as a response to the increased use of cannabis in 
recent years and the associated increase in the prison 
population sentenced for cannabis-related crimes in the 
UK, the Home Secretary encouraged the Advisory 
Council to consider rescheduling this drug under the 
Misuse of Drugs Act. The subsequent reclassification into 
class C rather than class B was intended to allow the 
downgrading of sentencing tariffs and reduce the prison 
problems; however, national and international political 
pressures led to a reversal of this decision within a few 
years.7,8 Further increases in the use of cannabis are 
anticipated over the next decade.1 
When used as a drug, cannabis is most commonly 
smoked; however, the form and method of smoking vary 
widely. For example, in Scotland, the majority of users 
smoke cannabis resin (a sappy substance secreted from 
the plant during the flowering phase supplied as a green 
resinous product, colloquially known as ‘soap bar’), 
which is cut with tobacco and smoked as a handmade 
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unfiltered cigarette known as a ‘joint’.9 The joint is often 
single skinned and unfiltered, although a roach (usually a 
small piece of rolled-up cardboard) may be employed to 
allow the user to hold the joint at a reasonable temperature. 
Cannabis resin, also known as hash, is smoked widely 
throughout Europe, but in the Americas the flowering tops 
and leaves of the plant (marijuana) predominate and the use 
of cannabis resin is limited.1 Cannabis may also be smoked 
through a modified water pipe known as a bong which 
draws the cannabis through water cooling the inhaled 
vapour. This method, while used in the UK and Europe, 
is perhaps more common in Australasia.1 
 
The widespread use of cannabis also appears to have been 
accompanied by an increase in the use of stronger ‘skunk’ 
cannabis or ‘sinsemilla’ (literally from the Spanish ‘without 
seed’). The potency of cannabis is, at present, determined 
by its content of D9THC, the primary active constituent. 
The greatest concentrations of D9THC are harvested 
from the unfertilised female plant; hence, sinsemilla 
provides the highest concentration. This form of cannabis 
is most easily cultivated indoors and attracts the use of 
colourful names such as ‘super-skunk’, ‘AK-47’ and ‘northern 
lights’, to name but a few. Whereas the concentration of 
D9THC may be around 2–4% in herbal cannabis, the 
concentration in sinsemilla (skunk) may approach 10% or 
15%. There is concern, particularly from police data on 
drug seizures, that the availability of skunk has increased 
dramatically in the UK within the past decade.10
The majority of cannabis research has focused on the 
psychiatric consequences and only limited attention has 
been given to the potential of cannabis to impact on the 
lung. The small number of studies that have examined 
the potential for cannabis to affect lung health have been 
undertaken in North America, Australia, New Zealand 
and North Africa; the remaining information is drawn 
from selected case reports and personal clinical 
experience and these have contributed to an emerging 
concern that cannabis may be linked to the development 
of chronic obstructive pulmonary disease (COPD), the 
presentation of pneumothorax, a predisposition to 
respiratory infections and, perhaps most worryingly, the 
development of lung cancer. Such research is particularly 
important when one considers that the majority of 
cannabis smokers are young and have yet to complete 
lung growth, which may make them particularly 
susceptible to any potential adverse effects.
cannaBiS and chronic oBSTrucTive 
Pulmonary diSeaSe
Chronic obstructive pulmonary disease has assumed 
major importance in the world health agenda. Current 
estimates suggest that the condition has a prevalence of 
around 1% in the general population, but this is probably 
higher in older age  groups.11  The condition is characterised 
by an accelerated loss of lung function and life-long 
disability. However, the increasing prevalence and 
potential impact of the disease may be most clearly seen 
in population mortality tables where COPD is predicted 
to become the world’s third leading cause of mortality 
by 2030.12
The definition of COPD embraces the concept that the 
condition may be invoked by an abnormal inflammatory 
response of the lung to noxious particles and gases.13 In 
this regard, the most important aetiological factor is 
tobacco smoking, but epidemiological and laboratory 
studies support the role of other noxious particles and 
gases such as coal dust, silica and particulate matter from 
biomass fuels. As the smoke from the cannabis joint 
contains a mixture of potentially noxious and injurious 
products, it is plausible that smoking cannabis may be 
linked to the development of COPD.
The potential for cannabis to be detrimental to lung 
health was first noted in studies undertaken in California 
when Tashkin and colleagues recruited a convenience 
sample of nearly 300 subjects aged 25–49 years who 
smoked at least ten joints per week or the equivalent of 
marijuana for at least five years.14 Applying a modified 
version of the American Thoracic Society/National 
Heart, Lung and Blood Institute respiratory questionnaire 
they found that the symptoms of acute and chronic 
bronchitis were substantially and significantly more 
prevalent among marijuana smokers compared with 
non-marijuana smokers of a similar age. The results were 
not affected by whether an individual smoked, or did not 
smoke, tobacco in addition to marijuana. 
Later North American studies examined the potential 
effects of cannabis smoking in the general population by 
investigating subjects enrolled in several large cohort 
studies.15–17 Bloom and colleagues reported data from a 
longitudinal household study from Tucson, Arizona.15 The 
seventh survey, undertaken from 1981 to 1983, included 
information on the duration and intensity of non-tobacco 
(assumed to be marijuana) smoking and the authors 
reported that the prevalence of respiratory symptoms 
such as phlegm and wheeze was increased in smokers of 
non-tobacco cigarettes.  As had been observed by Tashkin 
and colleagues, the results were not affected by whether 
or not the subjects had smoked additional tobacco.  
A further study from Tucson reporting respiratory 
symptoms and pulmonary function in nearly 2,000 
subjects aged 15–60 years found that compared with non-
smokers, smokers of non-tobacco cigarettes were almost 
two times more likely to report cough, chronic phlegm 
and wheeze.16 Symptoms were most prevalent in those 
who had smoked for several years and persisted despite 
quitting smoking. 
The third National Health and Nutrition Examination 
Survey (NHANES III) was used to report a much larger 
North American general population study in which 
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Moore and colleagues were able to include nearly 7,000 
adults aged 20–59 years.17 The use of marijuana (defined 
as self-reported 100+ lifetime use and at least one day 
of use in the past month) was accompanied by a variety 
of respiratory symptoms, including chronic bronchitis, 
coughing on most days, phlegm production, wheezing 
and chest sounds without a cold. Those who smoked 
both tobacco and marijuana had a greater prevalence of 
respiratory symptoms than those who smoked only 
tobacco. A potentially important public health message 
was that the marijuana users had similar rates of 
respiratory symptoms as tobacco users even though 
they were ten years younger. 
While the data on chronic bronchitis and other respiratory 
symptoms appear reasonably consistent between these 
different centres, the relationship between smoking 
cannabis and lung function remains less clear. In a 
longitudinal study of nearly 400 healthy Caucasian adults 
who smoked marijuana on a regular basis, Tashkin and 
colleagues found no significant adverse effect on lung 
function. The subjects in this study were predominantly 
men in their early thirties who had consumed an average 
of 3.5 joints per day for around five years.18 Although 
Moore and colleagues reported an initial observation that 
marijuana smoking was associated with an obstructive 
ventilatory defect, this disappeared when corrected for 
other potential confounding factors. However, both of 
the Tucson studies have suggested that smoking non-
tobacco cigarettes was associated with airways 
obstruction. A more detailed analysis of nearly 900 
people studied as part of a population-based study of 
obstructive lung disease being undertaken in Vancouver, 
Canada, has shown that regular cannabis smokers were 
nearly three times more likely than non-smokers to have 
COPD as defined by spirometric testing.19 
The data from New Zealand, where the other main 
body of literature on cannabis emerges, are similar. 
Taylor and colleagues selected a group of 20-year-old 
cannabis-dependent individuals who had been enrolled 
in the Dunedin Multidisciplinary Health and Development 
Study.20 After correcting for tobacco use the authors 
reported that compared with non-tobacco users, 
cannabis dependence was associated with an increased 
odds ratio of reporting respiratory symptoms such as 
cough and sputum, wheezing apart from colds, exercise-
induced shortness of breath and sputum production, 
nocturnal wakening and chest tightness. The frequency 
of reported symptoms was similar to subjects who 
smoked between one and ten cigarettes per day. Just 
over one-third of cannabis-dependent subjects had an 
obstructive ventilatory defect compared with around 
one-fifth of non-smokers; the outcomes were 
independent of co-existing bronchial asthma. A further 
longitudinal study from the same authors collected data 
at ages 18, 21 and 26.21 For each age an increasing use of 
cannabis was associated with a decline in first-second 
expiratory volume (FEV1)/vital capacity (VC); however, 
after controlling for possible confounding factors, only a 
marginal effect remained. There was no significant 
interaction between cannabis use and cigarette smoking, 
which suggested to the authors that cumulative cannabis 
use and daily cigarette smoking act in an additive fashion.
Investigators from the Greater  Wellington region reported 
data pertaining to symptoms, lung function and the 
prevalence of emphysema as measured by high-resolution 
computed tomography (CT) scan in a convenience sample 
of just over 300 adult subjects.22 Smoking cannabis 
(predominantly in the form of joints) was accompanied by 
chest tightness, wheeze, cough and chronic bronchitis and 
the presence of asthma diagnosed after the age of 16 
years. The effects of cannabis smoke and tobacco smoke 
were additive. Smoking cannabis was also associated with 
a dose-related impairment of airflow obstruction, large 
airways function and hyperinflation.  The authors estimated 
that, for measures of airflow obstruction, one cannabis 
joint had a similar effect to 2.5–5 tobacco cigarettes. 
However, while cannabis smoking was associated with 
decreased lung density on a high-resolution CT scan, in 
contrast to tobacco smoking, macroscopic emphysema 
was seldom observed.
Most recently, a population-based cohort study from 
Dunedin, New Zealand, has reported the effects of 
cannabis on the lung function of just over 1,000 subjects 
aged 32 years.23 Cannabis use was associated with higher 
lung volumes, hyperinflation and increased large-airways 
resistance, but there was little evidence for airflow 
obstruction or impairment of gas transfer, as seen with 
tobacco smoking. The authors suggested that cannabis 
appears to have different effects on lung structure 
and function from tobacco and is less likely to result 
in emphysema. 
These observations, although containing some 
contradictions and inconsistency, have contributed to an 
emerging concern among respiratory physicians that 
regular cannabis smoking may promote the development 
of COPD. Nonetheless, it remains uncertain whether 
cannabis smoking contributes to the development of 
emphysema. The data from New Zealand would suggest 
that the occurrence of emphysema is unusual in cannabis 
smokers; however, this appears to be frequently observed 
by UK chest physicians24 and selected case reports have 
published dramatic bullous disease.25,26  
Issues of ethnicity aside, one possible explanation for the 
apparent differences in the spectrum of pulmonary 
disease associated with cannabis use may relate to the 
type of cannabis available and the method of smoking.  As 
mentioned, the most common form of cannabis used in 
Scotland is cannabis resin, imported from North Africa, 
which is cut with tobacco and smoked as an unfiltered 
joint. The resin is often impure, being adulterated with a 
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range of other contaminants. In North America, cannabis 
is more usually supplied as marijuana, typically imported 
from Mexico and, particularly in the earlier studies, the 
herbal cannabis available is likely to have been of low 
potency compared with that available today. New 
Zealand imports very little cannabis, with much of it 
being grown wild or at home using hydroponic plants, 
and a greater number of users employ bongs.  These and 
other differences may be important in the pattern 
of disease observed and further studies are needed 
to investigate the effects of cannabis, given the 
potential public health agenda if so many young people 
smoke the drug.
cannaBiS and PneumoThorax
Selected case reports and small case series have hinted at 
an association between pneumothorax and cannabis 
smoking.27–29 In one series, 13 of 15 consecutive patients 
with spontaneous pneumomediastinum or subcutaneous 
emphysema admitted to using marijuana extensively 
before coming to hospital.30 More recently, Beshay and 
colleagues have reported the findings in 17 young regular 
marijuana smokers presenting with spontaneous 
pneumothorax with bullous emphysema, comparing them 
with the findings of non-marijuana smoking patients 
presenting during the same 30-month period.31 Computed 
tomography imaging of the lungs revealed multiple bullae 
at the apex or significant bullous emphysema. Also, in 
common with other reports, this dramatic emphysema 
occurred largely in the absence of spirometric 
abnormalities. Only two patients had reduced FEV1 and 
one reduced VC below 50% of predicted. This correlated 
with the subjectively asymptomatic condition of the 
patients. Histology showed severe lung emphysema, 
inflammation and heavily pigmented macrophages. 
This pathological description by Beshay and colleagues is 
reminiscent of the  Australian experience of ‘bong lung’. Gill 
reviewed the histopathology of ten known cannabis 
smokers (although several also used cocaine) who under-
went video-assisted thoracoscopic surgery and resection 
of bullae.32 All the marijuana smokers showed features of 
‘irregular emphysema’ with prominent irregularly dilated 
airspaces, cysts, blebs and bullae. In addition, they observed 
massive accumulation of intra-alveolar pigmented 
histiocytes (‘smokers’ macrophages’) with a desquamative 
interstitial pneumonia (DIP)-like appearance. However, in 
contrast to DIP, interstitial scarring and bullous disease 
were very prominent and there was no radiographical 
evidence of interstitial lung disease. Gill proposed that this 
DIP-like pattern with massive accumulation of pigmented 
histocytes and pulmonary apical cystic disease may be 
strongly suggestive of illegal drug use.
 
The occurrence of pneumothorax and the descriptions 
of bullous lung disease may lend some weight to the 
concerns that cannabis smoking is linked to bullous 
emphysema; however, not all of the subjects reported in 
these studies showed evidence of emphysema. 
cannaBiS and Pulmonary infecTionS
Cannabis exerts a variety of effects on inflammatory and 
immune cells and it seems credible to suggest that, as 
with regular tobacco smoking, regular cannabis smoking 
may be accompanied by an increased risk of respiratory 
infections. Moore and colleagues reported an increased 
odds ratio of self-reported pneumonia,17 but none of the 
other studies appear to have reported this endpoint. 
Smoking tobacco is known to be associated with an 
increased risk of developing tuberculosis (TB). To date, 
no studies have suggested the same from cannabis 
smoking, but there is evidence that the spread of  TB may 
be facilitated by the shared smoking of cannabis. 
Munckhof and colleagues reported a cluster of cases of 
TB occurring in young males from Queensland,  Australia, 
in whom marijuana smoking through bongs was common 
among cases and contacts.33 Although the most important 
risk factor for acquiring TB was close household contact 
with a case, sharing a bong with a case was associated 
with a more than doubled risk of pulmonary TB. 
Variants on the method of cannabis smoking have also 
been linked to an increased risk of TB transmission. For 
example, ‘hotboxing’ describes the behaviour of smoking 
marijuana inside a car with the windows closed so that 
users may repeatedly inhale exhaled smoke. Among 
users who reported or were observed hotboxing, the 
majority who received a tuberculin skin test had a 
positive result. ‘Shotgunning’ refers to inhaling smoke 
from illicit drugs, then exhaling it directly into another 
person’s mouth. Perhaps not surprisingly, this practice is 
associated with a high risk of TB transmission.34
The identification of fungal spores in cannabis plants has 
led to suggestions that smoking the drug may increase 
the risk of fungal respiratory infections. Pulmonary 
aspergillosis as a complication of bone marrow 
transplantion for chronic myeloid leukaemia has been 
reported in a patient who had smoked marijuana 
heavily.35 Cultures of the marijuana used by the individual 
revealed Aspergillus fumigatus with morphology and 
growth characteristics identical to the organism grown 
from open lung biopsy. Similar reports emphasise the 
potential importance of smoking cannabis in other 
immunosuppressed subjects.36,37
cannaBiS and lung cancer
The cannabis joint is qualitatively similar in terms of tar 
and carcinogen content to a standard cigarette. Several 
studies have demonstrated pre-cancerous histological 
and molecular abnormalities in the respiratory tracts of 
cannabis smokers, and the carcinogenic effects of 
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cannabis smoke have been demonstrated in in vitro and 
in vivo animal models. However, the problems inherent in 
the design and power of clinical studies that would 
provide strong evidence of an association between 
cannabis smoking and the subsequent development of 
lung cancer mean that robust evidence may be some 
way off. Nonetheless, the subject is attracting the 
attention of researchers. While some studies have failed 
to identify such links,38 several smaller studies have reported 
an increased risk of developing lung cancer in relation to 
smoking cannabis, as hinted at by the basic science. 
Investigators from Tunisia reported a hospital-based 
case-control study including 149 cases of lung cancer 
and 188 controls.39 As expected, tobacco smoking was 
significantly associated with an increased risk of lung 
cancer, with the greatest risks being seen in those that 
smoked the most; however, lung cancer was seen almost 
four times more frequently in individuals with past 
cannabis use (odds ratio 3.7, 95% confidence interval 
[CI] 1.8–7.5). The association remained statistically 
significant after adjustment for age, tobacco smoking and 
occupational exposure. 
A hospital-based case-control study from Casablanca, 
Morocco included 118 incident lung cancer cases and 
235 age-, sex- and residence-matched controls.40 While 
tobacco smoking and a history of chronic bronchitis 
were the strongest risk factors for lung cancer the 
combined use of hashish/kiff and snuff had an odds ratio 
of 6.67 (95% CI: 1.65–26.90) and the odds ratio for 
hashish/kiff (without snuff) was 1.93 (95% CI: 0.57–6.58). 
A further pooled analysis of three hospital-based case-
control studies in Tunisia, Morocco and Algeria identified 
a total of 430 cases and 778 controls (all male).41 
Adjusting for country, age, tobacco smoking and 
occupational exposure, the odds ratio for lung cancer 
was 2.4 (95% CI: 1.6–3.8) for ever cannabis smoking. This 
association remained after adjustment for lifetime 
tobacco pack-years as continuous variable. The odds 
ratio adjusted for intensity of tobacco smoking (cigarette/
day) among current tobacco smokers and never cannabis 
smokers was 10.9 (95% CI: 6.0–19.7) and the odds ratio 
among current tobacco users and ever cannabis smokers 
was 18.2 (95% CI: 8.0–41.0). The risk of lung cancer 
increased with increasing joint-years, but not with 
increasing dose or duration of cannabis smoking.
Aldington and colleagues conducted a case-control 
study of lung cancer in adults under the age of 55 years 
using the New Zealand Cancer Registry and hospital 
databases.42 Interviewer-administered questionnaires 
were used to assess possible risk factors, including 
cannabis use. In total, 79 cases of lung cancer and 324 
controls were included in the study. In this study those 
with the heaviest cannabis use (>10.5 joint-years of 
cannabis use) displayed an increased risk of lung cancer 
(relative risk 5.7 [95% CI 1.5–21.6]), after adjustment for 
confounding variables including cigarette smoking. 
Summary
Cannabis is a commonly used illegal drug that is mostly 
smoked. Although the potential adverse respiratory 
effects have received relatively little attention the studies 
that have been reported suggest that habitual smoking of 
cannabis may contribute to the development of 
COPD, pneumothorax, respiratory infections, including 
tuberculosis, and lung cancer. 
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1. The predominant method of taking cannabis in 
the UK is? 
A. Eating as hash cakes.
B. Smoking resin with tobacco rolled as a joint.
C. Smoking resin alone without tobacco rolled as a joint.
D. Smoking marijuana with tobacco rolled as a joint.
E. Smoking marijuana without tobacco rolled as a joint.
2.  Which one of the following is not true of cannabis?
A. D9THC may act to induce bronchial smooth muscle 
relaxation when taken acutely.
B. D9THC binds to naturally occurring receptors in the 
brain.
C. The plant grows slowly in a limited range of climatic 
conditions.
D. The plant can be difficult to cultivate indoors. 
E. The most potent forms of the drug are derived from 
female plants.
3. Which of the following is consistently reported in 
studies investigating regular cannabis smokers? 
A. Symptoms of chronic bronchitis.
B. An accelerated decline in FEV1.
C. The presence of bullous emphysema.
D. A decreased risk of pneumothorax.
E. A decreased risk of lung cancer.
SELF-ASSESSMENT QUESTIONS
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4.  Which of the following has not been reported in 
association with cannabis use?
A. Tuberculosis.
B. Pneumomediastinum.
C. Fungal lung infection. 
D. Pneumonia.
E. Pulmonary carcinoid.
5. Which one of the following statements is accurate?
A. The cannabis smoked in California is similar to that 
smoked in Scotland. 
B. Cannabis resin is a predominantly pure drug.
C. Pneumothorax has not been described in persons 
smoking cannabis through bongs. 
D. The risk of contracting tuberculosis may be increased 
by hotboxing.
E. The use of skunk is declining.
For the answers, please turn to page 382.
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